Sushmita Rath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sushmita Rath has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Sudeep Gupta
Homi Bhabha National Institute, Mumbai, Maharashtra, India
6 shared publications - Jyoti Bajpai
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
4 shared publications - Palak Popat
Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
4 shared publications - Prabhat Bhargava
Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
4 shared publications - Rajiv Sarin
Department of Radiation Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
4 shared publications - Anbarasan Sekar
Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
3 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 63 (2) , 180-185
Early clinical outcomes, treatment adherence, and toxicity profile of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: Real-world data from India
Background: Hormone receptor-positive (HR+)/HER2-negative (HER2−) early breast cancer (EBC) is associated with a persistent risk of recurrence despite optimal local therapy and adjuvant endocrine therapy, particularly in patients with high-risk clinicopathologic features. Adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated significant benefits in randomized clinical trials; however, real-world data from Indian populations remain limited. This study evaluates real-world outcomes, tolerability, and treatment adherence to adjuvant CDK4/6 inhibitors in HR+/HER2 − EBC patients treated at a tertiary cancer center in India. Methods: This single-center, retrospective observational study included consecutive adult patients with HR+/HER2 − EBC who received adjuvant endocrine therapy in combination with either ribociclib or abemaciclib following definitive surgery between January 2023 and December 2025. Demographic, clinicopathologic, treatment, toxicity, and outcome data were extracted from institutional medical records. Adverse events were graded using common terminology criteria for adverse events. The primary endpoints were treatment tolerability and invasive disease-free survival (iDFS). Secondary endpoints included overall survival, dose modifications, and treatment discontinuation rates. Survival outcomes were estimated using the Kaplan–Meier method. Results: A total of 75 patients (median age: 52 years) were analyzed. Stage III disease was present in 69.3% of patients, including IIIA/IIIB/IIIC, and ≥4 positive lymph nodes were observed in 70.6%, representing a high-risk group. Node-negative status was seen in 10 (13.3%) patients. Ribociclib was administered to 55.3% of patients and abemaciclib to 43.4% of patients, and dose modifications were required in 14.2% and 18.1% of patients, respectively, while permanent discontinuation occurred in 3.6% of ribociclib-treated patients and none in the abemaciclib group. Grade ≥3 toxicities were infrequent. In the ribociclib group, grade 3–4 neutropenia occurred in 6.0%, anemia in 4.7%, thrombocytopenia in 2.3%, and diarrhea in 2.3% of patients. In the abemaciclib group, grade 3–4 neutropenia was observed in 6.0%, anemia in 3.0%, thrombocytopenia in 3.0%, and diarrhea in 12.1%, the latter being the most frequent severe adverse event. At a median follow-up of 6.35 months, iDFS was 100% at 6 months and 90.6% at 12 months. Conclusion: In this real-world Indian cohort, adjuvant CDK4/6 inhibitors demonstrated favorable tolerability, low rates of severe toxicity and permanent discontinuation, and encouraging early disease control in high-risk HR+/HER2 − EBC patients. These findings support the feasibility and applicability of adjuvant CDK4/6 inhibitor therapy in routine clinical practice in India, while emphasizing the need for longer follow-up and larger multicenter studies.
- 1 April 2026
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 63 (2) , 180-185
Open AccessEarly clinical outcomes, treatment adherence, and toxicity profile of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: Real-world data from India
Background: Hormone receptor-positive (HR+)/HER2-negative (HER2−) early breast cancer (EBC) is associated with a persistent risk of recurrence despite optimal local therapy and adjuvant endocrine therapy, particularly in patients with high-risk clinicopathologic features. Adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated significant benefits in randomized clinical trials; however, real-world data from Indian populations remain limited. This study evaluates real-world outcomes, tolerability, and treatment adherence to adjuvant CDK4/6 inhibitors in HR+/HER2 − EBC patients treated at a tertiary cancer center in India. Methods: This single-center, retrospective observational study included consecutive adult patients with HR+/HER2 − EBC who received adjuvant endocrine therapy in combination with either ribociclib or abemaciclib following definitive surgery between January 2023 and December 2025. Demographic, clinicopathologic, treatment, toxicity, and outcome data were extracted from institutional medical records. Adverse events were graded using common terminology criteria for adverse events. The primary endpoints were treatment tolerability and invasive disease-free survival (iDFS). Secondary endpoints included overall survival, dose modifications, and treatment discontinuation rates. Survival outcomes were estimated using the Kaplan–Meier method. Results: A total of 75 patients (median age: 52 years) were analyzed. Stage III disease was present in 69.3% of patients, including IIIA/IIIB/IIIC, and ≥4 positive lymph nodes were observed in 70.6%, representing a high-risk group. Node-negative status was seen in 10 (13.3%) patients. Ribociclib was administered to 55.3% of patients and abemaciclib to 43.4% of patients, and dose modifications were required in 14.2% and 18.1% of patients, respectively, while permanent discontinuation occurred in 3.6% of ribociclib-treated patients and none in the abemaciclib group. Grade ≥3 toxicities were infrequent. In the ribociclib group, grade 3–4 neutropenia occurred in 6.0%, anemia in 4.7%, thrombocytopenia in 2.3%, and diarrhea in 2.3% of patients. In the abemaciclib group, grade 3–4 neutropenia was observed in 6.0%, anemia in 3.0%, thrombocytopenia in 3.0%, and diarrhea in 12.1%, the latter being the most frequent severe adverse event. At a median follow-up of 6.35 months, iDFS was 100% at 6 months and 90.6% at 12 months. Conclusion: In this real-world Indian cohort, adjuvant CDK4/6 inhibitors demonstrated favorable tolerability, low rates of severe toxicity and permanent discontinuation, and encouraging early disease control in high-risk HR+/HER2 − EBC patients. These findings support the feasibility and applicability of adjuvant CDK4/6 inhibitor therapy in routine clinical practice in India, while emphasizing the need for longer follow-up and larger multicenter studies.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (1)
Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial
PURPOSE: The AKT pathway is upregulated in cervical cancer. This trial aimed to investigate whether the protease AKT pathway inhibitor (nelfinavir mesylate), in addition to chemoradiation (CRT) and image-guided brachytherapy (IGBT), could improve disease-free survival (DFS). METHODS: NELCER (ClinicalTrials.gov identifier: NCT03256916 ), a phase III adaptive trial, randomly assigned patients with stage III cervical cancer (International Federation of Gynecology and Obstetrics 2018) to CRT and IGBT (standard arm) or in combination with nelfinavir (test arm). Patients in the test arm received nelfinavir 1,250 mg twice a day starting 7-10 days before and during CRT. The primary end point was 3-year DFS. Secondary end points included locoregional control, overall survival, adverse events, and quality of life. Disease-specific survival (DSS) was also estimated. The study planned to randomly assign 348 patients to detect a hazard ratio (HR) of 0.66. Futility analysis was scheduled at 32 events. RESULTS: Ninety-two patients were recruited at the time of futility analysis. The stage was IIIA-B (43.5%), IIIC1 (48.9%), and IIIC2 (7.6%) patients. The median prescribed dose to high-risk clinical target volume was 88 Gy 10 (IQR, 83.6-92 Gy 10 ). At a median follow-up of 34.9 months (29-40.8), the 3-year DFS was 71% (95% CI, 0.58 to 0.86) in the standard arm and 56% in the nelfinavir arm (95% CI, 0.43 to 0.70; HR, 1.34 [0.66 to 2.7]; P = .40). The nelfinavir arm had a higher incidence of acute grade ≥ 3 (8.7% v 0%, P = .04) GI effects. The 3-year DSS was 82% (95% CI, 0.70 to 0.95) in the standard arm and 57% (95% CI, 0.43 to 0.75) in the nelfinavir arm (HR of 1.97 [0.87 to 4.4], P = .09). The z-value was 0.74. CONCLUSION: The 3-year DFS did not cross prespecified statistical boundary; however, on the basis of DSS and acute adverse events, nelfinavir was not considered clinically efficacious, and the trial was stopped at the first interim analysis.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (1)
Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial
PURPOSE: The AKT pathway is upregulated in cervical cancer. This trial aimed to investigate whether the protease AKT pathway inhibitor (nelfinavir mesylate), in addition to chemoradiation (CRT) and image-guided brachytherapy (IGBT), could improve disease-free survival (DFS). METHODS: NELCER (ClinicalTrials.gov identifier: NCT03256916 ), a phase III adaptive trial, randomly assigned patients with stage III cervical cancer (International Federation of Gynecology and Obstetrics 2018) to CRT and IGBT (standard arm) or in combination with nelfinavir (test arm). Patients in the test arm received nelfinavir 1,250 mg twice a day starting 7-10 days before and during CRT. The primary end point was 3-year DFS. Secondary end points included locoregional control, overall survival, adverse events, and quality of life. Disease-specific survival (DSS) was also estimated. The study planned to randomly assign 348 patients to detect a hazard ratio (HR) of 0.66. Futility analysis was scheduled at 32 events. RESULTS: Ninety-two patients were recruited at the time of futility analysis. The stage was IIIA-B (43.5%), IIIC1 (48.9%), and IIIC2 (7.6%) patients. The median prescribed dose to high-risk clinical target volume was 88 Gy 10 (IQR, 83.6-92 Gy 10 ). At a median follow-up of 34.9 months (29-40.8), the 3-year DFS was 71% (95% CI, 0.58 to 0.86) in the standard arm and 56% in the nelfinavir arm (95% CI, 0.43 to 0.70; HR, 1.34 [0.66 to 2.7]; P = .40). The nelfinavir arm had a higher incidence of acute grade ≥ 3 (8.7% v 0%, P = .04) GI effects. The 3-year DSS was 82% (95% CI, 0.70 to 0.95) in the standard arm and 57% (95% CI, 0.43 to 0.75) in the nelfinavir arm (HR of 1.97 [0.87 to 4.4], P = .09). The z-value was 0.74. CONCLUSION: The 3-year DFS did not cross prespecified statistical boundary; however, on the basis of DSS and acute adverse events, nelfinavir was not considered clinically efficacious, and the trial was stopped at the first interim analysis.
- Top Cited PapersOpen Access
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (1) , 9-19
Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial
PURPOSE: We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). METHODS: In this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m 2 ) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study. RESULTS: Of 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified P = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal P = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal P = .003; 5-year EFS 75.0% v 59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal P = .002; 5-year OS 78.2% v 64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal P = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal P = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities. CONCLUSION: Carboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (1) , 9-19
Top Cited PapersOpen AccessAddition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial
PURPOSE: We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). METHODS: In this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m 2 ) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study. RESULTS: Of 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified P = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal P = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal P = .003; 5-year EFS 75.0% v 59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal P = .002; 5-year OS 78.2% v 64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal P = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal P = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities. CONCLUSION: Carboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400365
Retrospective Study to Determine Factors Influencing Outcome in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Neoadjuvant Chemotherapy
PURPOSE: There are scant data on patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer treated with neoadjuvant therapy (NAT) in real-world settings with limited access to HER2-targeted therapy. METHODS: This was a retrospective analysis of patients with nonmetastatic, HER2-positive breast cancer treated with NAT between January 2014 and December 2018 to determine factors affecting pathologic complete response (pCR), event-free survival (EFS), and overall survival (OS). RESULTS: The cohort comprised 1,004 patients with a median age of 47 years, 533 (53.1%) with clinical T3/T4 tumors, 466 (46.4%) with clinical N2/3 status, and 527 (52.5%) with hormone receptor–positive disease. Trastuzumab was given to 528 (52.6%) patients in the neoadjuvant setting and 711 (70.8%) patients in neoadjuvant and/or postoperative settings. pCR was achieved in 226 (22.5%) patients; the 5-year EFS in the whole cohort, pCR group, and no-pCR group was 63.5% (95% CI, 60.36 to 66.63), 86.1% (95% CI, 81.59 to 90.60), and 57% ([95% CI, 53.47 to 60.52]; P < .001), respectively. In multivariable analysis in the full cohort, smaller tumor size (cT1/T2 v cT3/T4), higher grade (III v II), hormone receptor–negative status, and use of neoadjuvant HER2-targeted therapy were significantly associated with higher pCR, and smaller tumor size (cT1/T2 v cT3/T4), lower node involvement (cN0/N1 v cN2/N3), achievement of pCR, and receiving trastuzumab were significantly associated with higher EFS and OS. CONCLUSION: In a setting with constrained access to HER2-targeted therapy, lower clinical tumor burden and receiving trastuzumab were significantly associated with increased pCR and survival in patients with HER2-positive breast cancer treated with NAT. Efforts should be made to enhance early diagnosis and access to HER2-targeted therapy worldwide.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400365
Retrospective Study to Determine Factors Influencing Outcome in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Neoadjuvant Chemotherapy
PURPOSE: There are scant data on patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer treated with neoadjuvant therapy (NAT) in real-world settings with limited access to HER2-targeted therapy. METHODS: This was a retrospective analysis of patients with nonmetastatic, HER2-positive breast cancer treated with NAT between January 2014 and December 2018 to determine factors affecting pathologic complete response (pCR), event-free survival (EFS), and overall survival (OS). RESULTS: The cohort comprised 1,004 patients with a median age of 47 years, 533 (53.1%) with clinical T3/T4 tumors, 466 (46.4%) with clinical N2/3 status, and 527 (52.5%) with hormone receptor–positive disease. Trastuzumab was given to 528 (52.6%) patients in the neoadjuvant setting and 711 (70.8%) patients in neoadjuvant and/or postoperative settings. pCR was achieved in 226 (22.5%) patients; the 5-year EFS in the whole cohort, pCR group, and no-pCR group was 63.5% (95% CI, 60.36 to 66.63), 86.1% (95% CI, 81.59 to 90.60), and 57% ([95% CI, 53.47 to 60.52]; P < .001), respectively. In multivariable analysis in the full cohort, smaller tumor size (cT1/T2 v cT3/T4), higher grade (III v II), hormone receptor–negative status, and use of neoadjuvant HER2-targeted therapy were significantly associated with higher pCR, and smaller tumor size (cT1/T2 v cT3/T4), lower node involvement (cN0/N1 v cN2/N3), achievement of pCR, and receiving trastuzumab were significantly associated with higher EFS and OS. CONCLUSION: In a setting with constrained access to HER2-targeted therapy, lower clinical tumor burden and receiving trastuzumab were significantly associated with increased pCR and survival in patients with HER2-positive breast cancer treated with NAT. Efforts should be made to enhance early diagnosis and access to HER2-targeted therapy worldwide.
- Open Access
- 1 February 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400142
Prognostic Modeling for Bone Sarcomas Based on a Large Prospective Cohort From a Tertiary Care Cancer Center in India
PURPOSE: Outcomes of adolescents and young adults (AYA) with bone sarcomas including osteosarcoma (OGS) and Ewing sarcoma (ES) are affected by various factors including inadvertent previous treatment and poor compliance. We aimed to develop a risk-scoring system derived and validated at a tertiary care cancer center in India. METHODS: All AYA OGS and ES cases treated at our institute with OGS-12 and Ewing’s family of tumors-2001 (EFT-2001) protocols from 2011 to 2021 and 2013 to 2018, respectively, were prospectively analyzed. Weighted scores provided to each prognostic variable on the basis of approximate ratios of the beta coefficients of each factor in the multivariable model were summated to divide patients into three clinically discriminatory risk groups, validated by applying separately to derivation, validation, and whole cohorts. RESULTS: Among 606 (81.0%) of 748 AYA with nonmetastatic OGS, significant factors included in the prognostic model were failure to complete protocol (hazard ratio [HR], 2.65), previous treatment (HR, 2.93), necrosis median (204 U/L; HR, 1.63). Of 104 (39.5%) of 263 AYA with ES, significant factors were failure to complete protocol (HR, 2.84), previous treatment (HR, 6.37), necrosis 8 cm (HR, 2.64). For 142 (38.8%) of 366 AYA with metastatic OGS, significant factors were failure to complete protocol (HR, 5.29), metastases not amenable to local treatment (HR, 1.96), necrosis 10 metastases (HR, 2.44). For 38 (43.6%) of 82 AYA with metastatic extremity ES, significant factors were failure to complete protocol (HR, 3.88) and metastases not amenable to local treatment (HR, 10.6). CONCLUSION: We developed simple, effective prognostic models for AYA with bone sarcomas with specific potential relevance for low- and middle-income countries.
- 1 February 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400142
Open AccessPrognostic Modeling for Bone Sarcomas Based on a Large Prospective Cohort From a Tertiary Care Cancer Center in India
PURPOSE: Outcomes of adolescents and young adults (AYA) with bone sarcomas including osteosarcoma (OGS) and Ewing sarcoma (ES) are affected by various factors including inadvertent previous treatment and poor compliance. We aimed to develop a risk-scoring system derived and validated at a tertiary care cancer center in India. METHODS: All AYA OGS and ES cases treated at our institute with OGS-12 and Ewing’s family of tumors-2001 (EFT-2001) protocols from 2011 to 2021 and 2013 to 2018, respectively, were prospectively analyzed. Weighted scores provided to each prognostic variable on the basis of approximate ratios of the beta coefficients of each factor in the multivariable model were summated to divide patients into three clinically discriminatory risk groups, validated by applying separately to derivation, validation, and whole cohorts. RESULTS: Among 606 (81.0%) of 748 AYA with nonmetastatic OGS, significant factors included in the prognostic model were failure to complete protocol (hazard ratio [HR], 2.65), previous treatment (HR, 2.93), necrosis median (204 U/L; HR, 1.63). Of 104 (39.5%) of 263 AYA with ES, significant factors were failure to complete protocol (HR, 2.84), previous treatment (HR, 6.37), necrosis 8 cm (HR, 2.64). For 142 (38.8%) of 366 AYA with metastatic OGS, significant factors were failure to complete protocol (HR, 5.29), metastases not amenable to local treatment (HR, 1.96), necrosis 10 metastases (HR, 2.44). For 38 (43.6%) of 82 AYA with metastatic extremity ES, significant factors were failure to complete protocol (HR, 3.88) and metastases not amenable to local treatment (HR, 10.6). CONCLUSION: We developed simple, effective prognostic models for AYA with bone sarcomas with specific potential relevance for low- and middle-income countries.
- Top Cited Papers
- 21 January 2024
- Published by Elsevier in The Lancet Oncology
- Vol. 25 (2) , 246-254
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
- 21 January 2024
- Published by Elsevier in The Lancet Oncology
- Vol. 25 (2) , 246-254
Top Cited PapersLow-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial